Oncosec Medical (ONCS) Tops Q2 EPS by 5c

Oncosec Medical (NASDAQ: ONCS) reported Q2 EPS of ($0.27), $0.05 better than the analyst estimate of ($0.32).

At January 31, 2017, OncoSec had $20.5 million in cash and cash equivalents, as compared to $28.7 million of cash and cash equivalents at July 31, 2016. OncoSec expects these funds to be sufficient to allow it to continue to operate its business for at least the next 12 months.

For earnings history and earnings-related data on Oncosec Medical (ONCS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Reading (RDI) Tops Q2 EPS by 4c